Cardiovascular

FDA approves Impavido to treat leishmaniasis

On March 19, the U.S. Food and Drug Administration (FDA) approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares